, on behalf of the UK JSLE Study Group Abstract Objective. To determine whether mucocutaneous manifestations are associated with major organ involvement in a UK national cohort of juvenile-onset SLE (JSLE) patients.
Introduction
Juvenile-onset SLE (JSLE) is one of the most severe and chronic autoimmune diseases in children, with 1520% of all patients developing signs and symptoms in childhood [1, 2] . The incidence of JSLE is 0.30.9 per 100 000 children each year, while non-Caucasians, especially Hispanics, African Americans and Asian populations, have higher incidence of disease [3] .
Despite JSLE patients having a notably improved quality of life and higher 10-year survival rates over the past few decades, the disease remains incurable, with severe and at times difficult to manage disease and treatment complications [4, 5] . JSLE patients with protracted active, relapsing or uncontrollable disease have higher mortality rates due to multi-organ involvement, opportunistic infections and treatment side effects [69] .
The diagnosis of JSLE is often based on scoring a minimum of 4 of the 11 criteria of the ACR (1997 revision) guidelines before the age of 17 years [10] . Notably, the first four criteria (malar rash, discoid rash, photosensitivity and oral ulcers) are mucocutaneous manifestations, which are very common in children. These lesions are easily detected clinically and relate specifically to systemic disease activity and severity, in particular, malar rash and oral ulcers [6, 1114] . The lesions are often useful in monitoring disease flare alongside routine laboratory investigations. Other mucocutaneous lesions that are not included in the ACR criteria, but are included in other disease activity indices [15, 16] , are also common and may be associated with disease severity [11, 12, 17, 18] .
The paediatric adaptation of the 2004 update of the BILAG index (pBILAG-2004) for children with SLE [19, 20] is used routinely in the assessment of JSLE patients in the UK. There are nine different organ-based domains in the pBILAG-2004 index, which contains additional clinical and laboratory features for each category included in the ACR criteria. For example, the mucocutaneous domain in the pBILAG-2004 index includes skin eruption (maculopapular lupus rash), non-scaring alopecia and angioedema lesions. Another organ-based domain related to mucocutaneous manifestations is vasculitis, which includes cutaneous vasculitis, RP and livedo reticularis.
This study analysed the relative frequency of mucocutaneous manifestations and their relation to other organ involvements by using disaggregated ACR criteria and the pBILAG-2004 index in this UK cohort of patients. In particular, we determined whether mucocutaneous manifestations are associated with involvement of major organs (renal, haematological and neurological) and disease severity.
Patients and methods
The UK JSLE Study Group, established in 2006, is a collaborative network from almost all clinical centres managing JSLE patients across the UK. The data collection and data repository of the UK JSLE Cohort Study has previously been described [20] . All patients were recruited to the UK JSLE Cohort Study between 2006 and 2012 and those diagnosed with definite or probable JSLE before the age of 17 years were eligible for inclusion and their clinical features were reviewed. Written informed assent/consent forms were received from all patients and their parents. Ethics approval for this study was obtained from the Multicentre Research Ethics Committee. Patient information, including disease activity, severity and damage scores were collected prospectively to monitor the development/evolution of disease over time. Patients whose diagnosis fulfilled four or more of the ACR criteria for SLE were included in this study and divided into two groups. The first group-ACR skin feature positive-consisted of patients that had developed at least one of four skin manifestations according to the ACR criteria (malar rash, discoid rash, photosensitivity and oral ulcers) at the time of diagnosis. The second group-ACR skin feature negative-fulfilled the diagnostic criteria, but without any positive skin involvement at diagnosis.
Patient information was collected to provide demographic data, age at diagnosis of lupus, family history of lupus and other autoimmune diseases and possible trigger factors, including medications and sunlight. The ACR criteria and the pBILAG-2004 index at the time of diagnosis were reviewed and analysed in each patient group. All patients were followed up every 3 months, or at the time of a disease flare, and all details according to the organbased domains of the pBILAG-2004 index were recorded at every visit. ACR criteria and SLICC/ACR Damage Index [21] scores were collected annually using bespoke annual assessment forms. The database for pBILAG-2004 disease activity scores within each organ-based BILAG domain was described in our previous study [20] . In brief, the scores were alphabetically assigned as follows: A, severe disease activity requiring systemic corticosteroids or immunomodulators; B, moderate disease activity requiring symptomatic treatments, such as low-dose corticosteroids, antimalarial drugs or NSAIDs; C, mild disease not requiring treatment; D, inactive disease, but with previously affected organs; E, no record of previous organ or system involvement. The disease activity scores were applied to each organ-based BILAG domain. Statistical analyses were performed by using SPSS version 20 
Results

Patients and demographic data
Of the 306 patients recruited from 15 centres from across the UK, 242 patients with JSLE fulfilled four or more of the ACR criteria at the time of diagnosis. One had missing/ incomplete data, so a total of 241 patients were included in this study. The remaining 64 patients had a clinician's diagnosis of JSLE but met only two or three of the ACR criteria and were excluded. The ACR skin feature positive group consisted of 179 patients (74%) while the ACR skin feature negative group comprised 62 patients (26%). Table 1 presents the demographic, family history, potential triggers and duration of follow-up for both groups of patients. There was no significant difference for age at diagnosis, gender or duration of follow-up between the groups. Sunlight was reported as an important potential trigger factor in 24% of ACR skin feature positive patients (n = 44), compared with 6% of ACR skin feature negative patients (n = 4, P < 0.05). Table 2 Table 2 . At the latest follow-up, using ACR criteria, only 16 patients (9%) had developed other organ involvement. For example, the prevalence of nephritis increased from 46 (25%) to 60 (33%) patients (data not shown).
Disaggregated ACR criteria
The second group, ACR skin feature negative patients (n = 62), showed significant differences in the spectrum of organ involvement compared with the skin feature positive group (Table 2) . ACR skin feature negative patients had a significantly higher occurrence of non-erosive arthritis [n = 49 (79%) vs n = 107 (60%), P < 0.05], LN [n = 27 (43%) vs n = 46 (26%), P < 0.05] and neurological involvement [n = 10 (16%) vs n = 6 (3%), P = 0.001] compared with the skin feature positive group. Significantly, more ACR skin feature negative patients showed immunological [n = 58 (93%), P < 0.01] and haematological abnormalities [n = 52 (84%), P < 0.05] and more presented with haemolytic anaemia [n = 22 (35%), P < 0.05]. Only 10 patients (16%) from this group went on to develop skin involvement as defined by the ACR criteria. Nine patients developed photosensitivity (14%), five patients (8%) developed discoid rash, photosensitivity and oral ulcers, and none developed any further systemic organ involvement (data not shown).
Disease activity and disease damage scores Table 3 presents the disease activity and damage scores for both patient groups. There were no statistically Demographic data of the patients diagnosed with JSLE who fulfilled four or more of the ACR criteria for SLE (n = 241) in the UK JSLE Cohort Study. The patients were divided into two separate groups according to the ACR criteria: ACR skin feature positive (n = 179) and ACR skin feature negative (n = 62). Pearson's chi-squared test was performed (*P-value < 0.05). JSLE: juvenile-onset SLE; pBILAG-2004: 2004 British Isles Lupus Assessment Group index.
significant differences in disease or damage scores between groups over time.
Disaggregated pBILAG-2004 score
Of the 179 ACR skin feature positive patients, 171 had mucocutaneous involvement as assessed by the pBILAG-2004 mucocutaneous domain, which included 65 patients (36%) with moderate to severe disease activity (score A or B), 106 patients (59%) with inactive to mild disease activity (score C or D) and 8 patients (4%) with no mucocutaneous involvement (score E) (Fig. 1A) . The relative frequency of mucocutaneous lesions is shown in supplementary Fig. S1 , available at Rheumatology Online. Twenty-six ACR skin feature negative patients (42%) had mucocutaneous involvement as defined by the Number and percentage of ACR skin feature-positive and ACR skin feature-negative patients at the time of diagnosis. Pearson chi-squared test was performed (*P < 0.05, **P < 0.01, ***P < 0.005). www.rheumatology.oxfordjournals.org pBILAG-2004 index in the mucocutaneous domain at diagnosis: 11 patients (18%) had a score of A or B and 15 patients (24%) had a score of C or D. The lesions included mild skin eruption (maculopapular lupus rash), diffuse or patchy non-scaring alopecia, cutaneous vasculitis, RP, livedo reticularis, mild mucosal ulcers and mild angioedema (Fig. 1B) . Moreover, 8 of 11 patients whose score was A or B had diffuse or patchy non-scarring alopecia, and all of them had maculopapular lupus rash, cutaneous vasculitis and RP.
Major organ or systemic involvement Fig. 2 shows the pBILAG-2004 scores of both groups of patients who had moderate to severe mucocutaneous involvement (score A or B in the mucocutaneous domain), including 65 ACR skin feature positive patients and 11 ACR skin feature negative patients. The results showed that 34% (22/65) of ACR skin feature positive patients had evidence of moderate to severe renal involvement (score A or B in the renal domain), while 73% (8/11) ACR skin feature negative patients had severe renal disease (P < 0.05). Moderate to severe haematological involvement (score A or B in the haematology domain) was found in 16 patients (25%) of 65 ACR skin feature positive patients, but was found in 6 of 11 ACR skin featurenegative patients (54%, P < 0.05) ( Fig. 2A) . During the course of the study, 43 of the 65 (66%) ACR skin feature positive patients with moderate to severe mucocutaneous involvement by the pBILAG-2004 index subsequently developed moderate to severe renal involvement and 34 (52%) developed haematological involvement. In contrast, all ACR skin feature negative patients with moderate to severe mucocutaneous involvement [n = 11 (100%)] developed both moderate to severe renal and haematological involvement at some point in the period of follow-up (P < 0.05 for both) (Fig. 2B) . Fig. 3 summarizes medication usage over the course of the follow-up period for both groups of patients. Of the 179 ACR skin featurepositive patients, significantly more had received HCQ [n = 139 (78%), P < 0.01] and oral prednisolone [n = 139 (78%), P < 0.01] than the skin feature negative group. In contrast, of the 62 ACR skin feature negative patients, a greater number of patients had received immunosuppressive drugs compared with the skin feature positive group: 28 (45%, P < 0.01) patients received MMF, 16 (26%, P = 0.06) received CYC and 15 (24%, P = 0.5) received MTX (Fig. 3) . 
Medication usage
Discussion
Mucocutaneous manifestations are the second most common organ involvement in JSLE after haematological involvement, with 6085% of patients developing skin manifestations by the time of diagnosis [6] . Malar (butterfly) rash, photosensitivity, oral ulcers and discoid rash are hallmarks of skin manifestations in JSLE and are included in the ACR classification criteria. In this national study of UK JSLE patients, 74% of JSLE patients had skin involvement at diagnosis, consistent with previous studies [6, 8, 22] .
In this study, JSLE patients were divided into two groups, those with and those without skin manifestations (as defined by the ACR criteria) at diagnosis, i.e. ACR skin feature positive and ACR skin feature negative patients. Demographics, disease activity and damage scores and duration of follow-up data were comparable between the two groups. Notably, sunlight (observed by patients) was an important and significantly more common trigger factor in ACR skin feature positive patients, supporting evidence that skin lesions are sensitive to sunlight and aggravated by sun exposure [2325] . However, no seasonal variation was noted at disease onset in our cohort study.
Previous studies using the ACR criteria have reported a positive relationship between cutaneous lupus lesions, including malar rash and oral ulcers, and systemic disease activity and severity [6, 1114] . Therefore those patients with skin manifestations of lupus who fulfilled the ACR criteria may have been expected to have increased major systemic organ involvement and more severe disease activity compared with those without skin involvement. It is interesting to note that in this study we conversely observed a significantly higher incidence of major organ involvement in those individuals who did not have skin manifestations as part of the diagnostic data set.
Recently, nailfold capillaroscopy abnormalities have been used as an additional measure of disease activity [26, 27] . It would be interesting to see whether this measure had a positive correlation with major organ involvement. However, nailfold capillaroscopy measurements were not routinely used in our study and therefore no specific data are available to analyse.
When the disaggregated ACR classification criteria were analysed, haemolytic anaemia, non-erosive arthritis, nephritis and neurological involvement were statistically significantly increased in individuals without skin involvement. This result indicates an important clinical paradigm, FIG. 2 pBILAG-2004 scores of both groups of patients who had moderate to severe mucocutaneous involvement Percentage of ACR skin feature positive (ACR skin, n = 65) and ACR skin feature negative (ACR non-skin, n = 11) patients who had moderate to severe mucocutaneous involvement by p-BILAG 2004 score and had score A or B in three major organ-based BILAG domains at the time of diagnosis (A), or had at least once passed score A or B from the time of diagnosis until the latest follow-up (B). Score A or B: moderate to severe involvement; score C or D or E: inactive or stable or no symptoms. Pearson Chi-square test was performed (*P<0.05, **P<0.01).
www.rheumatology.oxfordjournals.org principally that patients who fulfil the ACR criteria but who do not have skin signs at diagnosis of SLE are more likely to have other major organ involvement. Since diagnosis of JSLE in patients without skin lesions requires other positive ACR criteria in order to fulfil four or more criteria for diagnosis, the relative weighting of other organ involvement is likely to be increased.
Comparison of overall disease activity and damage scores between groups using the pBILAG-2004 and the SLICC/ACR Damage Index were not significantly different. However, in ACR skin feature negative patients the use of immunosuppressive therapies, such as MMF, was more common. Whether these therapies protected and limited disease severity, progression and other organ involvement is currently unknown.
When a diagnosis is dependent on fulfilling four or more criteria, then there will inevitably be a range of possible organ involvement and subsequent therapy will be influenced by initial disease activity. Those individuals presenting with renal, neurological or haematological manifestations of the disease will require systemic immunosuppression to obtain disease control. Those presenting with skin and musculoskeletal manifestations may initially require only immunomodulatory drugs, such as HCQ. Overall, these data suggest that JSLE patients without skin involvement (using the ACR criteria) generally present with more severe disease than those with skin involvement. Visible mucocutaneous signs may allow early diagnosis before more internal organ involvement develops, while those without these features may take longer to be recognized and diagnosed.
There are a number of other important mucocutaneous manifestations commonly found in JSLE patients apart from the four listed in the ACR criteria. Among the ACR skin featurenegative patients (i.e. undetected using ACR criteria at the time of diagnosis), 42% actually had mucocutaneous involvement according to the pBILAG-2004. The lesions included maculopapular lupus rash, diffuse or patchy non-scarring alopecia, cutaneous vasculitis and RP. Moreover, 18% of these patients had moderate to severe mucocutaneous involvement (score A or B) at the time of diagnosis. This finding indicated that important and clinically significant mucocutaneous manifestations also commonly occur in JSLE patients. These additional lesions are also associated with systemic disease activity and severity [11, 12, 17, 28] . Therefore this study further investigated these manifestations in ACR skin featurenegative patients using the pBILAG-2004 index.
Patients who did not have skin lesions (as defined by the ACR diagnostic criteria) but had other major mucocutaneous manifestations of the disease (score A or B) had a significantly higher incidence of renal and haematological disease at the time of diagnosis and during the follow-up period compared with those with skin disease. These ACR skin featurenegative patients had maculopapular lupus rash, diffuse or patchy non-scarring alopecia, cutaneous vasculitis and RP. Therefore other non-specific mucocutaneous skin lesions (apart from the four in the ACR criteria) may be more effective predictors in JSLE patients and should perhaps be more explicit in lupus diagnostic criteria.
In spite of the fact that the 1997 revised ACR classification criteria have been widely used as standard criteria for making a diagnosis of JSLE, it is recognized that they have limitations, especially for paediatric patients. A recent study from the SLICC group [29] has proposed an alternative SLICC classification criteria for SLE and included more mucocutaneous manifestations in the clinical criteria, such as acute cutaneous lupus (including maculopapular lupus rash), other forms of chronic cutaneous lupus and non-scarring alopecia. The group demonstrated that the SLICC classification criteria showed better sensitivity and more clinical relevance compared with the ACR criteria, which led to more patients being diagnosed with SLE. This present study supports this proposed need for revision of the classification criteria. The SLICC SLE classification criteria need prospective validation in JSLE patients.
In conclusion, mucocutaneous manifestations are very common in JSLE patients. The current ACR diagnostic criteria focus on mucocutaneous manifestations of disease that may not fully reflect systemic disease severity or major organ involvement. Our study supports the proposal that the classification criteria for SLE need to be revised .   FIG. 3 Medication use over the course of the follow-up period for both groups of patients Medication usage among patients in ACR skin feature positive (ACR skin, n = 179) and ACR skin feature negative (ACR non-skin, n = 62) groups at any time over the course of the follow-up period. Pearson Chi-square test was performed (**P<0.01).
Rheumatology key messages
. Juvenile-onset SLE (JSLE) patients without the four ACR mucocutaneous criteria had increased risk of major organ involvement. . Mucocutaneous manifestations not included in the ACR criteria were clinically relevant in JSLE patients. . Diagnostic criteria for SLE/JSLE should consider inclusion of mucocutaneous features not within the current ACR criteria.
